> Disappointed by poor efficacy data from two Phase III trials of Tavocept, Japan's Takeda announced that it has told BioNumerik Pharmaceuticals that it may scrap their licensing deal on the drug. Report
> The FDA has approved Abbott's Humira for an inflammatory disease of the spine and spinal joints. Report
> Shares of CytRx ticked up on its release of positive data from a Phase I trial of its HIV vaccine DP6-001. CytRx says the trial successfully demonstrated both HIV-specific T-cell and antibody immune responses. Researchers will file a summary of the data with the FDA next month. Report
> Roche Holding AG says that both Avastin and Xeloda met their primary endpoints in a Phase III trial for colorectal cancer. Report
> Repligen says that it was won a summary judgment against ImClone in its patent case regarding the cell line used in making Erbitux. Repligen and MIT allege that the cell line was created under contract for the National Cancer Institute by a predecessor to Repligen and subsequently transferred from the NCI to ImClone for use in research and development only. Release
> The FDA has accepted Merck's NDA for MK-0431A--a combination of Januvia and metformin for Type 2 diabetes--for standard review. Report
> Napo Pharmaceuticals made a good impression in its debut on the London exchange, rising eight percent. Napo concentrates its research on AIDS diarrhoea, Irritable Bowel Syndrome, acute infectious diarrhoea and paediatric diarrhea. Report
> Momenta Pharmaceuticals has filed an IND for its lead candidate, M118, for acute coronary syndromes. Release
> Schering AG has voluntarily recalled its contrast agent Ultravist Injection 370 mgl/ml. Report
And Finally… It's getting easier and easier to make customized viruses, and fears continue to grow of its possible use by bioterrorists. Article